{"id":"NCT00048542","sponsor":"Abbott","briefTitle":"Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-09","primaryCompletion":"2005-01","completion":"2010-06","firstPosted":"2002-11-05","resultsPosted":"2010-01-11","lastUpdate":"2011-08-22"},"enrollment":171,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Juvenile Idiopathic"],"interventions":[{"type":"BIOLOGICAL","name":"Double-Blind Adalimumab/Placebo + MTX","otherNames":["ABT-D2E7","Humira"]},{"type":"BIOLOGICAL","name":"Double-Blind Adalimumab/Placebo","otherNames":["ABT-D2E7","Humira"]},{"type":"DRUG","name":"OLE BSA Adalimumab +/- MTX","otherNames":["ABT-D2E7","Humira"]},{"type":"DRUG","name":"OLE FD Adalimumab +/- MTX","otherNames":["ABT-D2E7","Humira"]}],"arms":[{"label":"Double-Blind Adalimumab + MTX","type":"EXPERIMENTAL"},{"label":"Double-Blind Placebo + MTX","type":"PLACEBO_COMPARATOR"},{"label":"Double-Blind Adalimumab","type":"EXPERIMENTAL"},{"label":"Double-Blind Placebo","type":"PLACEBO_COMPARATOR"},{"label":"OLE BSA Adalimumab + MTX","type":"EXPERIMENTAL"},{"label":"OLE BSA Adalimumab","type":"EXPERIMENTAL"},{"label":"OLE FD Adalimumab + MTX","type":"EXPERIMENTAL"},{"label":"OLE FD Adalimumab","type":"EXPERIMENTAL"}],"summary":"This is a multicenter, Phase 3 randomized, placebo-controlled study designed to evaluate adalimumab in children 4 to 17 years old with polyarticular juvenile idiopathic arthritis (JIA) who are either methotrexate (MTX) treated or non-MTX treated.","primaryOutcome":{"measure":"Number of Subjects in the Non-MTX Stratum With Disease Flare During the Double-Blind Phase","timeFrame":"Week 16 to Week 48 (32 weeks)","effectByArm":[{"arm":"Double-Blind Adalimumab","deltaMin":13,"sd":null},{"arm":"Double-Blind Placebo","deltaMin":20,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.031"}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":4},"locations":{"siteCount":31,"countries":["United States","Belgium","Czechia","France","Germany","Italy","Slovakia","Spain"]},"refs":{"pmids":["30054164","18716298"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":38},"commonTop":["Upper respiratory tract infection","Viral infection","Injection site pain","Headache","Nasopharyngitis"]}}